13F HOLDINGS REPORT
REGENERON PHARMACEUTICALS, INC.
Quarter ended Q2 2025 · Filed August 1, 2025 · Accession 0001104659-25-073115
Total Value
$1.49B
Positions
4
Other Managers
0
Confidential Omitted
No
Holdings (4)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Alnylam Pharmaceuticals, Inc. | ALNY | 4,444,445 | $1.45B | 97.60% |
| 2 | Intellia Therapeutics, Inc. | NTLA | 3,702,995 | $34.7M | 2.34% |
| 3 | Adicet Bio, Inc. | ACET | 968,183 | $590,592 | 0.04% |
| 4 | Adverum Biotechnologies, Inc. | 00773U207 | 180,909 | $388,954 | 0.03% |